Anna Marabotti
Socio Ordinario
Professore associato
Università di Salerno
Contact Information
email
website
RESEARCH AREA
biological data modelling,sequence analysis,structural genomics,structure analysis
RESEARCH ACTIVITY
Study of the structure-activity-dynamics relationships of various enzymes and proteins In particular:
• Study of protein-ligands and protein-DNA interactions
• Study of protein systems involved in various diseases (cancer, galactosemia)
• Study of interactions between ligands with pharmacological activity and proteins
• Study of protein-ligands and protein-DNA interactions
• Study of protein systems involved in various diseases (cancer, galactosemia)
• Study of interactions between ligands with pharmacological activity and proteins
SELECTED PUBLICATIONS
1) Marabotti A, Scafuri B, Facchiano A. Predicting the stability of mutant proteins by computational approaches: an overview. Brief Bioinform. 2020 Jun 3:bbaa074. doi: 10.1093/bib/bbaa074. Epub ahead of print. PMID: 32496523.
2) d'Acierno A, Scafuri B, Facchiano A, Marabotti A. The evolution of a Web resource: The Galactosemia Proteins Database 2.0. Hum Mutat. (2018), 39, 52-60.
3) Scafuri B, Varriale A, Facchiano A, D'Auria S, Raggi ME, Marabotti A. Binding of mycotoxins to proteins involved in neuronal plasticity: a combined in silico/wet investigation. Sci Rep (2017), 7, 15156.
4) Verdino A, Vigliotta G, Giordano D, Caputo I, Soriente A, De Rosa M, Marabotti A. Synthesis and biological evaluation of the progenitor of a new class of cephalosporin analogues, with a particular focus on structure-based computational analysis. PLoS One (2017), 12, e0181563.
5) Dubey A, Facchiano A, Ramteke PW, Marabotti A. In silico approach to find chymase inhibitors among biogenic compounds. Future Med Chem (2016), 8, 841-51.
6) Lai K, Boxer MB, Marabotti A. GALK inhibitors for classic galactosemia. Future Med Chem (2014), 6, 1003-15.
7) Chiappori F, Merelli I, Milanesi L, Marabotti A. Static and dynamic interactions between GALK enzyme and known inhibitors: guidelines to design new drugs for galactosemic patients. Eur J Med Chem (2013), 63, 423-434.
8) Boutron A, Marabotti A, Facchiano A, Cheillan D, Zatera M, Oliveira C, Costa C, Labrune P, Brivet M and French Galactosemia working group. Mutation spectrum in the French cohort of galactosemic patients and structural simulation of 27 novel missense mutations. Mol Genet Metab (2012), 107, 438-444.
9) Marabotti A and Facchiano A. Critical assessment of side chain conformation prediction in modelling of single point amino acid mutation. Adv Exp Med Biol (2010), 680, 283-289.
10) Facchiano A, Marabotti A. Analysis of galactosemia-linked mutations of GALT enzyme using a computational biology approach” PEDS (2010), 23, 103-113.
2) d'Acierno A, Scafuri B, Facchiano A, Marabotti A. The evolution of a Web resource: The Galactosemia Proteins Database 2.0. Hum Mutat. (2018), 39, 52-60.
3) Scafuri B, Varriale A, Facchiano A, D'Auria S, Raggi ME, Marabotti A. Binding of mycotoxins to proteins involved in neuronal plasticity: a combined in silico/wet investigation. Sci Rep (2017), 7, 15156.
4) Verdino A, Vigliotta G, Giordano D, Caputo I, Soriente A, De Rosa M, Marabotti A. Synthesis and biological evaluation of the progenitor of a new class of cephalosporin analogues, with a particular focus on structure-based computational analysis. PLoS One (2017), 12, e0181563.
5) Dubey A, Facchiano A, Ramteke PW, Marabotti A. In silico approach to find chymase inhibitors among biogenic compounds. Future Med Chem (2016), 8, 841-51.
6) Lai K, Boxer MB, Marabotti A. GALK inhibitors for classic galactosemia. Future Med Chem (2014), 6, 1003-15.
7) Chiappori F, Merelli I, Milanesi L, Marabotti A. Static and dynamic interactions between GALK enzyme and known inhibitors: guidelines to design new drugs for galactosemic patients. Eur J Med Chem (2013), 63, 423-434.
8) Boutron A, Marabotti A, Facchiano A, Cheillan D, Zatera M, Oliveira C, Costa C, Labrune P, Brivet M and French Galactosemia working group. Mutation spectrum in the French cohort of galactosemic patients and structural simulation of 27 novel missense mutations. Mol Genet Metab (2012), 107, 438-444.
9) Marabotti A and Facchiano A. Critical assessment of side chain conformation prediction in modelling of single point amino acid mutation. Adv Exp Med Biol (2010), 680, 283-289.
10) Facchiano A, Marabotti A. Analysis of galactosemia-linked mutations of GALT enzyme using a computational biology approach” PEDS (2010), 23, 103-113.
OTHER MEMBERSHIPS
ISCB, SIB
EDITORIAL BOARDS
Member of the Editorial Board of Scientific Reports (Nature Publishing group)
Member of the Editorial Board of Frontiers
Member of the Editorial Board of Current Chemical Biology (Bentham publisher)
Member of the Editorial Board of Frontiers
Member of the Editorial Board of Current Chemical Biology (Bentham publisher)
MAIN TEACHINGS
Biochimica Avanzata (ssd BIO/10, 6 CFU), Corso di Laurea Magistrale in Biologia, Università degli Studi di Salerno
Principi di Chimica Biologica (ssd BIO/10, 6 CFU), Corso di Laurea Triennale in Chimica, Università degli Studi di Salerno
Metodologie analitiche e biomolecolari, modulo Metodologie Biomolecolari (ssd BIO/10, 6 CFU), Corso di laurea Triennale in Scienze Biologiche, Università degli Studi di Salerno
Principi di Interattomica (ssd BIO/10, 1 CFU), Dottorato in Scienze Chimiche, Biologiche ed Ambientali, Università degli Studi di Salerno
Principi di Chimica Biologica (ssd BIO/10, 6 CFU), Corso di Laurea Triennale in Chimica, Università degli Studi di Salerno
Metodologie analitiche e biomolecolari, modulo Metodologie Biomolecolari (ssd BIO/10, 6 CFU), Corso di laurea Triennale in Scienze Biologiche, Università degli Studi di Salerno
Principi di Interattomica (ssd BIO/10, 1 CFU), Dottorato in Scienze Chimiche, Biologiche ed Ambientali, Università degli Studi di Salerno
